|Bid||50.63 x 800|
|Ask||50.91 x 4000|
|Day's Range||50.48 - 51.33|
|52 Week Range||41.45 - 61.71|
|Beta (5Y Monthly)||0.64|
|PE Ratio (TTM)||29.82|
|Earnings Date||Feb 06, 2023 - Feb 10, 2023|
|Forward Dividend & Yield||1.60 (3.51%)|
|Ex-Dividend Date||Nov 03, 2022|
|1y Target Est||N/A|
In this article, we take a look at the 10 biggest issues in the world and the companies working on solving them. You can skip our detailed analysis of the plight of the world and go directly to 5 Biggest Issues in the World and The Companies Working on Solving Them. The world is currently […]
Shares of Prometheus Biosciences (NASDAQ: RXDX) were down more than 12% this week as of Friday morning, according to data from S&P Global Intelligence. The clinical-stage biotech company specializes in immunotherapies with a focus on inflammatory bowel disease (IBD). Prometheus' lead therapy in its pipeline is IBD drug PRA023.
Roivant Sciences (ROIV), Pfizer's (PFE) new Vant company will take care of funding the global development of RVT-3101 in inflammatory and fibrotic diseases.